@article{cd92cfea2eb545409cecea8dcf2dea53,
title = "Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma",
keywords = "B-cell non-Hodgkin lymphoma, CD22+, antibody-drug conjugate, inotuzumab ozogamicin, rituximab",
author = "Dang, {Nam H.} and Michinori Ogura and Sylvie Castaigne and Fayad, {Luis E.} and Mats Jerkeman and John Radford and Antonio Pezzutto and Igor Bondarenko and Stewart, {Douglas A.} and Michael Shnaidman and Sharon Sullivan and Erik Vandendries and Kensei Tobinai and Radhakrishnan Ramchandren and Hamlin, {Paul A.} and Eva Gin{\'e} and Kiyoshi Ando",
note = "Funding Information: This study was sponsored by Pfizer Inc. Editorial support was provided by Simon J. Slater, PhD, of Complete Healthcare Communications, LLC, which was funded by Pfizer Inc.",
year = "2018",
month = aug,
doi = "10.1111/bjh.14820",
language = "English (US)",
volume = "182",
pages = "583--586",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",
}